SvarLifeScience

About us SvarLifeScience

Life science is always asking new questions. It’s essential to the discovery process.

As science moves forward, we get more and more innovative tools and techniques that will change the clinical mainstream. Someone has to provide stable and reliable solutions for identifying the right techniques and generating solid data from them. That’s where we come in.

Svar is a Swedish life science company that invent, develop and apply the best assay technology for drug development and clinical diagnostics with the goal to deliver new solutions tailored to customer requirements. We establish practical platforms for clinical routine testing, work to secure relevant competences by sharing best practices and knowledge and our partnerships enable us to deliver flexible solutions depending on specific needs.

We work to deliver the right answers at the right time to improve patient care and accelerate drug development. You can be sure of our answers: we’ve been working right across the clinical diagnostic value chain for more than 30 years.

Who we are and what we do

We are specialists in autoimmunity, inflammatory diseases and oncology, providing tailored cell-based and immunoassays and dedicated laboratory solutions for biopharma companies and clinical diagnostic labs through our worldwide partner network.

Simply put, we can provide the answers that our customers need throughout the entire drug development value chain – from early discovery through the clinical phases – in addition to tools for effective patient diagnosis and monitoring.

By helping to push the boundaries in drug discovery and clinical diagnostics, we contribute to the improvement of patient care.

Svar means answers in Swedish. If you have questions, we can help you find the right answers. Ask us today.

Nearly 30 years of accurate assay solution development

As a global supplier and partner within drug discovery and clinical diagnostics, Svar Life Science has 28 years of experience serving the life science market with diagnostic laboratory services aimed at helping customers move forward in the drug development process and ensuring optimal treatment of patients by providing accurate assay solutions for the clinical diagnostic laboratory.

Our strong Scandinavian roots are embodied in a high-quality, responsive, people- and solution-focused business. Through mergers, acquisitions, in-house innovation, industry collaboration and knowledge exchange, we continue to find and harness the optimal solutions for improved patient care and accelerated drug development.

SvarLifeScience 2018 - Euro Diagnostica becomes Svar Life Science

In 2018 Euro Diagnostica changed its name to Svar Life Science. Our new name, which means answers in Swedish, reflects our values and Scandinavian heritage, and positions us for doing business in life science.

SvarLifeScience 2014 - Acquisition of Biomonitor A/S and the iLite® technology

In 2014 we acquired Danish life science company Biomonitor A/S adding the iLite® technology and cell-based reporter gene assays to the product portfolio.  This addition enabled us to expand our offering to encompass the entire drug development value chain.

This included sales of iLite to biopharma and CROs, establishment of patient monitoring through lab developed tests in the US, and the building of a dedicated bioanalytical services unit.

SvarLifeScience 2011 - Acquisition of Vita Diagnostika GmbH 

In 2011, we further strengthened our offering and expertise with the acquisition of Vita Diagnostika GmbH.

SvarLifeScience 2007 - Launch of new CCPoint assay

The new CCPoint assay was launched in 2007. Today this assay is part of the European League Against Rheumatism (EULAR) and American College of Rheumatology (ACR) criteria for rheumatoid arthritis and is present on most major platforms around the world.

SvarLifeScience 2004 - Acquisition of Wieslab

In 2004 our company expanded its services with the acquisition of Wieslab, a specialist autoimmunity testing laboratory. These services continue to be provided to pharma, CRO and biotech companies by Wieslab Diagnostic and Bioanalytical Services.

SvarLifeScience 2002 - Anti-CCP2, a ground-breaking innovation

A ground-breaking innovation in 2002 was the Anti-CCP2, which contributed to the early diagnosis of rheumatoid arthritis.

SvarLifeScience 2001 - Development of Chromogranin A RIA

In 2001, Chromogranin A RIA was developed for the diagnosis of neuro-endocrine tumors and the calprotectin assay for diagnosis and patient management of inflammatory bowel disease (IBD).

SvarLifeScience 1992 - The Origin

The origins of Svar date back to 1992, when Euro Diagnostica was established in Malm?, Sweden following a merger between Ferring Diagnostica, Balticor Diagnostica, Euro Diagnostics and Medscand Diagnostics (MILAB). The company offered assay solutions to clinical laboratories and diagnostic platform providers. This included ANCA tests, to serologically detect autoimmune vasculitis.